Clinical trials: Clinically Significant Prostate Cancer
Prostate Cancer
The Development and Validation of MRI-AI-based Predictive Models for csPCa
This study retrospectively included patients who underwent prostate magnetic resonance imaging (MRI) and subsequent ultrasound-guided prostate biopsy at Peking University First Hospital from January 2019 to December 2023, and…
- Trial name
- NCT06842264
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Peking University First Hospital
Prostate Carcinoma
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen [PSMA] imaging agent) with positron emission tomography (PET)/computed tomography (CT) can…
- Trial name
- NCT07164027
- Testing
- Biopsy of Prostate, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer (Diagnosis), Clinically Significant Prostate Cancer
Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction
This is a multicenter observational study. A deep learning model integrated with multimodal imaging and digital pathology spatial registration is built based on preoperative multiparametric magnetic resonance imaging, transrectal…
- Trial name
- NCT07614256
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Guangxi Medical University
Prostate Cancer
Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform
In this non-interventional study, men being seen by urologists in the course of their normal practice that present with clinical suspicion of prostate cancer (based on DRE, elevated Prostate Specific Antigen (PSA), and/or family…
- Trial name
- NCT04100811
- Where
- 3 sites in United States
- Volunteers
- 2,019 people
- Sponsor
- miR Scientific LLC
PROSTATE CANCER, Prostate Biopsy
Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection
The goal of this cohort study is to investigate multiparametric ultrasound versus multiparametric MRI for clinically significant prostate cancer detection in patients scheduled for initial biopsy.
- Trial name
- TRUSVSMPMRI (NCT06183905)
- Testing
- Prostate imaging, Prostate biopsy
- Where
- China
- Volunteers
- 635 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Prostate Cancer
Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason Score of ≤ 3+4 severity who are candidates for active…
- Trial name
- proSPECT-AS (NCT02615067)
- Testing
- 99mTc-MIP-1404 Injection, Whole-Body Planar and pelvic SPECT/CT scan
- Where
- 45 sites in United States, Canada
- Volunteers
- 531 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostate Cancer
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
The purpose of this study is to find out how best to detect clinically significant lesions of prostate cancer by using micro-ultrasound technology (ExactVu) and by multiparametric magnetic-resonance imaging (mpMRI).
- Trial name
- OU-SCC-PROBX (NCT05471128)
- Testing
- Standard of Care Biopsy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Oklahoma
Prostate Cancer
Detection of Clinically Significant Prostate Cancer Using a Urinary Multimarker Sensor
This trial aims to develop and validate the urinary multimarker sensor which can measure trace amounts of biomarkers from naturally voided urine in men referred with clinical suspicion of prostate cancer who have had no prior…
- Trial name
- NCT04825002
- Testing
- Urinary multimarker sensor
- Where
- South Korea
- Volunteers
- 800 people
- Sponsor
- Asan Medical Center
Prostate Cancer, Active Surveillance for Prostate Cancer
Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance
Active surveillance is a common approach for men with low-risk or favorable intermediate-risk prostate cancer, aimed at avoiding or delaying treatment while closely monitoring the disease.
- Conditions
- Prostate Cancer, Active Surveillance for Prostate Cancer, Imaging Techniques
- Trial name
- MUS-AS (NCT07386171)
- Testing
- Micro-Ultrasound (mUS)
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Prostate Cancer
Targeted Cryoablation of Prostate Cancer Lesions: An Investigator-initiated Trial
This clinical trial is to provide a minimally invasive treatment option in which the targeted prostate cancer tissue is killed by cryoablation at extremely low temperatures only in the specific area of cancer "that should be…
- Trial name
- PROCRY (NCT05500846)
- Testing
- The Visual Ice Cryoablation System
- Where
- 2 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Osamu Ukimura
Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis)
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI…
- Trial name
- ECETEP (NCT07766122)
- Testing
- Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Prostate Cancer
TULIP ReTrain Study
This prospective clinical study aims to retrain and validate the PCaVision AI algorithm for the detection and localization of clinically significant prostate cancer (csPCa) using multiparametric ultrasound (mpUS) with two…
- Trial name
- TULIP ReTrain (NCT06974539)
- Testing
- Multiparametric ultrasound with contrast (Sonovue and Optison)
- Where
- Netherlands
- Volunteers
- 212 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Prostate Cancer, Prostate Neoplasm
MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection
With the general acceptance of MRI and technical advances in biopsy technique of the prostate, new questions arise concerning the selection of patients, the approach, the appropriate technique, the lesions to target and the…
- Trial name
- PROSOVI (NCT03819751)
- Testing
- MRI-targeted prostate biopsy
- Where
- Belgium
- Volunteers
- 96 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer (Diagnosis), Prostatic Neoplasms
Real-time Fluorescence Microscopy for Intraoperative Assessment of Prostate Biopsy Cores (FLASH)
Current prostate cancer diagnosis relies on MRI-targeted biopsy combined with a 12-core systematic biopsy. The systematic component is a major driver of overdiagnosis of insignificant cancer and biopsy-related morbidity, and…
- Trial name
- FLASH (NCT07846592)
- Testing
- Ex vivo real-time fluorescence microscopy of prostate biopsy cores (EndoScell system, model MES-1000P)
- Volunteers
- 450 people
- Sponsor
- Shanghai East Hospital
Prostate Cancer
Validation of a Machine Learning Model Based on MR for the Prediction of Prostate Cancer
The goal of this observational study is to validate a clinically significant predictive machine learning model based on the processing of images RMmp (Multiparametric Magnetic Resonance Imaging).
- Trial name
- NCT06773598
- Where
- Italy
- Volunteers
- 1,100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prostate Cancer
European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection
The goal of this clinical trial is to learn if a new ultrasound-based imaging method (PCaVision) can accurately detect clinically significant prostate cancer in adult men (18 years and older) who are either undergoing initial…
- Trial name
- PCaVISTA (NCT06935487)
- Testing
- transrectal ultrasound of prostate (TRUS) with AI software algorithm, MRI prostate
- Where
- 10 sites in France, Germany and 4 more
- Volunteers
- 806 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Prostate Cancer
Extended Systematic Versus Mri-Assisted pRostate Transperineal Biopsy
This is a randomized controlled trial to evaluate the detection of clinically significant prostate cancer (csPCa) by MRI-targeted approach (MRI-arm) versus 24-core transperineal (TP) systematic biopsy (TP-arm).
- Trial name
- SMART (NCT04685928)
- Testing
- MRI and MRI-guided prostate biopsy, TP-arm Systematic biopsy
- Where
- 8 sites in Hong Kong
- Volunteers
- 403 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Combination of PSA/DRE and Multi Parametric Magnetic Resonance Imaging
This randomized prospective multi center study is designed to confirm a new diagnostic pathway in primary diagnosis of clinically significant prostate cancer by combination of serum levels of prostate specific antigen (PSA)…
- Trial name
- PRIMA (NCT04993508)
- Testing
- PSA test, multiparametric prostate Magnetic Resonance Imaging (mpMRI), targeted MRI/US fusion-guided biopsy
- Volunteers
- 1,908 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Clinical Suspicion of Prostate Cancer
Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer.
This project aims to evaluate the role of fully hybrid PET/MRI with 18FPSMA and multiparametric MR imaging (mpMRI) as one-stop approach for the diagnosis of clinically significant prostate cancer (csPCa).
- Trial name
- RF2021-1237227 (NCT06305390)
- Testing
- PET/MRI
- Where
- Italy
- Volunteers
- 167 people
- Sponsor
- IRCCS San Raffaele
Randomized Controlled Trial, Prostate Cancer
Comparing Bp-MRI and Mp-MRI for Prostate Cancer Screening Accuracy
3.1 Study Objectives: 3.1.1 Primary objective: The investigators aim to address these questions for Taiwan males suspicious of csPCA, with PSA range of 4-20 ng/ml by conducting a RCT trial.
- Conditions
- Randomized Controlled Trial, Prostate Cancer, Magnetic Resonance Imaging
- Trial name
- NCT06402552
- Testing
- bp-MRI prostate, mp-MRI prostate
- Where
- Taiwan
- Volunteers
- 370 people
- Sponsor
- Chang Gung Memorial Hospital